Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rob White

News: Therapy Watch HCV expands into 4 additional EU markets

The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space...

Research Partnership

- PMLiVE

Can biosimilars live up to the hype?

Carol Lynch, chair of the European Generic Medicines Association, wants new biosimilars therapies to become routine

Biogen Idec building

Biogen’s CEO Scangos to step down

Departure comes as multiple sclerosis drug Tecfidera achieves improved sales growth

Infographic: HIV Market Snapshot

Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...

Research Partnership

Webinar: What next for biosimilars?

Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST

Research Partnership

- PMLiVE

Tracking comms trends: communication and market access

From multi-disciplinary teamwork to pharma’s reputation, value and access to global briefs, our contributors tackle some of the key topics in communications today

Syneos Health®

- PMLiVE

Tracking comms trends: communication and market access

From multi-disciplinary teamwork to pharma’s reputation, value and access to global briefs, our contributors tackle some of the key topics in communications today

China drug medicine pharma prices

Pfizer earmarks $350m for first Asian biotech facility

US pharma giant looks to tap into China’s pharmaceuticals market

- PMLiVE

Defining value: has anyone asked the patient?

The real-world challenges they face give patients unique views on 'value'

Biosimilars – the Brexit of the pharmaceutical industry?

In this article, Senior Consultant Jenna Earl explains what factors influence the uptake of biosimilars in the UK, comparing them to the same principles that help us navigate the complexities...

Blue Latitude Health

- PMLiVE

Biosimilar trastuzumab comparable to brand, ASCO hears

Roche’s Herceptin matched in safety and efficacy by Mylan and Biocon’s breast cancer drug

Free Thinking: Are biosimilars the answer to the rising cost of RA treatment?

In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy...

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links